Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗
Rezolute, Inc. entered into an underwriting agreement for a public offering of 22,040,976 shares of common stock and 3,800,000 pre-funded warrants, expected to raise gross proceeds of approximately $100 million. The financing was led by Frazier Life Sciences and is intended to fund commercialization preparation for ersodetug and general corporate purposes.
Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism. The study met its primary efficacy endpoint with 13 of 16 participants achieving at least a 50% reduction in glucose infusion rate, including 12 who completely discontinued IV glucose. The company expects to report full topline results in mid-December 2026 and engage with the FDA in Q1 2027.
Rezolute, Inc. reported financial results for its first fiscal quarter ended September 30, 2026, ending the period with $90.0 million in cash and investments. The company provided clinical updates on its ersodetug program, noting that enrollment is complete for the Phase 3 upLIFT study in tumor HI with topline results expected in December 2026, and plans to submit a BLA for one or both HI indications in 2027.
Rezolute, Inc. released an updated corporate investor presentation on October 29, 2026, highlighting its late-stage clinical programs for ersodetug in treating refractory hypoglycemia. The company reported a cash position of $108 million, providing a projected operational runway through the first quarter of 2028.
Rezolute announced the completion of patient enrollment in its Phase 3 upLIFT study of ersodetug for the treatment of tumor hyperinsulinism. The company expects to release topline data from the 16-participant registrational study in mid-December 2026.
Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug in congenital hyperinsulinism (HI) following a review of Phase 3 sunRIZE data. Although the trial missed its primary and key secondary endpoints, the Agency encouraged the meeting as a precursor to a potential Biologics License Application (BLA) submission. The company is also awaiting Phase 3 upLIFT results in tumor HI this quarter to finalize its overall regulatory strategy.
Counterparty
FDA
“We appreciate FDA’s thorough review of the extensive body of data generated in sunRIZE and are encouraged by the Agency’s recognition that this data will require in-depth evaluation during a formal BLA review.”
Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute
Rezolute, Inc. reported its financial results for the fourth quarter and full fiscal year ended June 30, 2026. The company highlighted clinical progress in its Phase 3 upLIFT study for tumor hyperinsulinism (HI), with topline results expected by the end of 2026, while its Phase 3 sunRIZE study in congenital HI remains under FDA review after failing to meet its primary endpoint.
Term
FY2026
“The past year was marked by significant progress across our clinical programs, particularly with the positive interim data from our upLIFT study in tumor HI. We remain focused on completing enrollment and delivering topline results as we work toward providing a potential new treatment option for patients suffering from refractory hypoglycemia.”